PCN164 COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.360
https://www.valueinhealthjournal.com/article/S1098-3015(19)32738-X/fulltext
Title :
PCN164 COST-EFFECTIVENESS OF DACOMITINIB VS. GEFITINIB AS FIRST-LINE TREATMENT FOR EGFR MUTATION POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER IN CHINA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32738-X&doi=10.1016/j.jval.2019.09.360
First page :
Section Title :
Open access? :
No
Section Order :
10296